MG-O-1002

MG-O-1002 is a small molecule drug developed as a topical ocular therapy for neovascular (wet) age-related macular degeneration (nAMD). It acts as an inhibitor of vascular endothelial growth factor (VEGF), aiming to reduce abnormal blood vessel growth and leakage in the retina. Unlike current anti-VEGF therapies that require intravitreal injection, MG-O-1002 is formulated as an eye drop, potentially offering a safer and more accessible self-administered alternative. The drug has demonstrated clear anti-VEGF effects in clinical studies with no reported corneal toxicity in animal models. Its unique formulation is designed to deliver sufficient concentrations to the posterior segment of the eye[1][4][3].

Other names

MG-O-1002MG-O1002MG-O 1002MG O 1002TO-O-1002TO-O1002TO-O 1002